| STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line. | |
| | |
MedLine Citation:
|
PMID: 19440213 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Classical Hodgkin lymphoma (cHL) is a malignant lymphoid disorder characterized by aberrant activation of signaling pathways. Constitutive activation of several components of the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway has been observed in Hodgkin and Reed/Sternberg cells, the tumor cells of cHL. In this study, we investigate the function of STAT6 in cHL cell lines and show that STAT6 promotes survival of these cells. Microarray expression analysis of STAT6-shRNA (short hairpin RNA)-expressing cHL cell lines was carried out to analyze the STAT6-mediated survival mechanism. Some of the identified genes with potentially important regulatory functions were also interleukin (IL)-4 dependently regulated in Ramos B cells and binding of STAT6 to the regulatory regions of several genes could be confirmed, indicating that these are direct STAT6 target genes. Importantly, STAT6 knockdown increased the expression and activation of STAT1 as well as the expression of known STAT1 target genes, indicating a cross-regulation between these signaling molecules. Forced expression of STAT1 was able to induce apoptosis in cHL cell line L1236. These findings indicate that both STAT6 and STAT1 can act as important antagonistic regulators in the pathogenesis of cHL. |
| | |
Authors:
|
D Baus; F Nonnenmacher; S Jankowski; C Döring; C Bräutigam; M Frank; M-L Hansmann; E Pfitzner |
Related Documents
:
|
7687873 - The 12q13-q15 translocation breakpoints in pleomorphic adenoma and clear-cell sarcoma o... 3116233 - Differences in gonadotrophin concentrations and pituitary responsiveness to gnrh betwee... 21916843 - Mecp2 and rett syndrome: reversibility and potential avenues for therapy. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-05-14 |
Journal Detail:
|
Title: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K Volume: 23 ISSN: 1476-5551 ISO Abbreviation: Leukemia Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-10-14 Completed Date: 2009-11-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8704895 Medline TA: Leukemia Country: England |
Other Details:
|
Languages: eng Pagination: 1885-93 Citation Subset: IM |
Affiliation:
|
Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Apoptosis Cell Proliferation Cell Survival / physiology* Chromatin Immunoprecipitation Flow Cytometry Gene Expression Profiling Gene Expression Regulation, Neoplastic Hodgkin Disease / genetics, metabolism, pathology* Humans Immunoblotting Oligonucleotide Array Sequence Analysis RNA, Messenger / genetics, metabolism RNA, Small Interfering / pharmacology Reverse Transcriptase Polymerase Chain Reaction STAT1 Transcription Factor / physiology* STAT6 Transcription Factor / physiology* Signal Transduction Tumor Cells, Cultured |
| Chemical | |
Reg. No./Substance:
|
0/RNA, Messenger; 0/RNA, Small Interfering; 0/STAT1 Transcription Factor; 0/STAT1 protein, human; 0/STAT6 Transcription Factor; 0/STAT6 protein, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Aortic pulse pressure and atherosclerotic structural alterations of coronary arteries.
Next Document: Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine ther...